Ovid Therapeutics Inc. (NASDAQ:OVID) previous close was $4.28 while the outstanding shares total 66.09M. The firm has a beta of 1.80, a 12-month trailing P/E ratio of 2.73. OVID’s shares traded higher over the last trading session, gaining 3.27% on 06/02/21. The shares fell to a low of $4.16 before closing at $4.42. Intraday shares traded counted 1.04 million, which was 68.04% higher than its 30-day average trading volume of 3.26M. The stock’s Relative Strength Index (RSI) is 69.97, with weekly volatility at 6.97% and ATR at 0.24. The OVID stock’s 52-week price range has touched low of $2.25 and a $9.40 high.
Investors have identified the Biotechnology company Ovid Therapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $305.47 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Ovid Therapeutics Inc. (OVID) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 236.66 million total, with 16.35 million as their total liabilities.
OVID were able to record 160.89 million as free cash flow during the 08/12/2021 quarter of the year, this saw their quarterly net cash flow reduce by 161.02 million. In cash movements, the company had a total of 160.9 million as operating cash flow.
Potential earnings growth for Ovid Therapeutics Inc. (OVID)
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 208.38 million trying to sell their products during the last quarter, with the result yielding a gross income of 31.83 million. This allows shareholders to hold on to 66.09M with the recently reported earning now reading 2.66 cents per share. This is a figure that compared to analyst’s prediction for their 08/12/2021 (2.53 cents a share).
Having a look at the company’s valuation, the company is expected to record -0.75 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on OVID sounds very interesting.
Is the stock of OVID attractive?
In related news, CEO, LEVIN JEREMY M bought 8,488 shares of the company’s stock in a transaction that recorded on Aug 28. The purchase was performed at an average price of 5.84, for a total value of 49,570. In the last 6 months, insiders have changed their ownership in shares of company stock by 31.04%.
3 out of 7 analysts covering the stock have rated it a Buy, while 4 have maintained a Hold recommendation on Ovid Therapeutics Inc.. 0 analysts has assigned a Sell rating on the OVID stock. The 12-month mean consensus price target for the company’s shares has been set at $6.00.